Bone Biologics Corp Common Stock
Compare this stock
BBLG Stock Report Card
$
24%
Performance
Score:
10/100
BBLG returned -94.35% in the last 12 months. Based on SPY's performance of 9.73%, its performance is below average giving it a score of 10 of 100.
Technicals
Score:
14/100
BBLG receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.
Earnings
Score:
49/100
BBLG has missed earnings 2 times in the last 20 quarters.
Profit
Score:
10/100
Out of the last 20 quarters, BBLG has had 1 profitable quarters and has increased their profits year over year on 1 of them.
Volatility
Score:
46/100
BBLG has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.
Bone Biologics Corp Common Stock Summary
Nasdaq / BBLG
Healthcare
Medical - Devices
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
BBLG scored poorly on our reportcard. Here are some similar companies and how they performed.
